Navigation Links
SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
Date:12/9/2010

MELVILLE, N.Y., Dec. 9, 2010 /PRNewswire/ -- Sequel Systems, Inc., a dynamic, service-oriented healthcare technology company, announced today that its Electronic Medical Record SequelMed EMR version 8, has been tested and certified by the Ohio Board of Pharmacy.  Prior approval by the Board of Pharmacy is required for all electronic prescription transmission systems intended to be used in Ohio. The Board approval process includes reviewing systems such as SequelMed EMR version 8 to ensure that it has true "positive identification" of the prescriber sending the prescription as defined by the Ohio Administrative Code (OAC). In addition to that, every system must have security and accountability of all confidential information, that the pharmacist receiving the prescription can identify that the system has approvable status with the Board of Pharmacy, and that the pharmacist receiving the prescription can identify that the prescription is legitimate.

(Logo:  http://photos.prnewswire.com/prnh/20101115/NY01712LOGO)

SequelMed e-Prescribe, the Electronic Prescribing software, is designed to eliminate prescription errors with use of electronic prescriptions and speed up the transfer of information between healthcare professionals and pharmacies. The accuracy of e-prescribing technology allows healthcare professionals to safely and securely transfer prescriptions to the pharmacies through electronic prescription tools using Sequel Systems' e-Prescription software.

According to a guide published by the e-Health Initiative Foundation in collaboration with AMA, AAFP, ACOP, MGMA and CIMM, e-prescribing can improve patient safety, medication compliance, prescribing accuracy and efficiency and reduce health care costs through averted adverse drug events and substitution of less expensive drug alternative.  The same guide also reported that recent research by the American Medical Association found that, due to these benefits physicians who use an e-prescribing system are significantly more satisfied with their prescribing process than physicians who continue to handwrite prescriptions.  Collectively, these enhancements will lead to a higher quality health care system that will benefit everyone.

For more information on how you can begin e-prescribing with SequelMed, please contact us at 800.965.2728 or email us at sequelmed@sequelmed.com.CONTACT: Amanda Leitl-Scanlan Sequel Systems, Inc. 631-694-3600 aleitl@sequelmed.comAbout Sequel SystemsSequel Systems, Inc. is a dynamic service-oriented company that develops software to simplify the complex practice and medical records management needs of healthcare providers while maximizing revenue and streamlining operations. Sequel Systems' suite of flexible, easy-to-use and comprehensive SequelMed® solutions includes practice management, electronic medical records, document management, e-prescribing and financial systems scaled to fit the needs of the small, medium and large enterprises. Today, Sequel Systems' solutions are in use by more than 12,000 physicians in all 50 states to provide the best possible care to patients through the use of technology. For more information about Sequel Systems, visit www.sequelmed.com.

About Ohio Board of PharmacyThe Ohio State Board of Pharmacy is the single State agency in Ohio responsible for administering and enforcing laws governing the legal distribution of drugs. The Board is also responsible for regulating the legal distribution of dangerous drugs in Ohio and ensuring the quality of all drugs administered, prescribed, dispensed by prescription, or sold over-the-counter.


'/>"/>

SOURCE Sequel Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
2. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
3. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
6. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
7. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
8. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
9. Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
10. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
11. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 BioLineRx ... in-licensing and developing promising therapeutic candidates, presents positive Phase 2a ... the Company,s leading oncology platform at the ongoing 58th American ... San Diego, California . ... , , ...
(Date:12/5/2016)... The global  non-invasive prenatal testing market  is anticipated ... by Grand View Research, Inc. Evolution of prenatal testing in the form ... screening and invasive diagnostic testing to determine the likelihood of fetal abnormality ... forecast period. Continue Reading ... ...
(Date:12/4/2016)... -- Johnson & Weaver, LLP announces that a class action ... Holdings, Inc. (NYSE: ZBH )  securities during the ... "Class Period"). Zimmer Biomet provides musculoskeletal healthcare products ... such as knee and hip reconstructive products. ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Routine ... measurements are consistently correct. However, regular performance testing is often neglected because ... a solution: SmartCal™ . This innovative test substance offers a fast ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
Breaking Medicine News(10 mins):